||Recombinant Human STAMBP (Accession # O95630), fused with , was produced in Spodoptera frugiperda, Sf 21 (baculovirus)-derived.
||Baculovirus Sf21 Insect Cells
||X mg/ml (X µM) in 50 mM HEPES pH 8.0, 150 mM NaCl,10% Glycerol (v/v), 1 mM TCEP
||Recombinant Human AMSH is a Ubiquitin-specific deconjugating enzyme. Reaction conditions will need to be optimized for each specific application. We recommend an initial Recombinant Human AMSH concentration of 100-500 nM. AMSH activity is partially or fully inhibited by DTT at concentrations above 1 mM.
||Recombinant Human STAMBP has a calculated MW of 48 kDa.
||>85%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).